The emerging safety profile of JAK inhibitors in rheumatic disease

Research output: Contribution to journalReview articlepeer-review

354 Scopus citations


Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently being tested in phase II and III trials for the treatment of a variety of autoimmune inflammatory diseases. Whereas a characteristic safety profile is emerging for some JAK inhibitors, differences between individual agents might emerge on the basis of distinct potency against their molecular targets. Similarly to biological therapy, JAK inhibition can lead to serious and opportunistic infections, and viral infections seem to be particularly frequent. Although no malignancy signals have been identified to date, long-term follow-up and further research are needed to understand the risk of malignancy associated with these compounds. As is the case for biologic agents, vaccination is important to mitigate the risks of these emerging therapies.

Original languageEnglish (US)
Pages (from-to)234-243
Number of pages10
JournalNature Reviews Rheumatology
Issue number4
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'The emerging safety profile of JAK inhibitors in rheumatic disease'. Together they form a unique fingerprint.

Cite this